ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 3160

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

4 sessions
Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Watch now
The PARAGLIDE-HF Trial Watch now
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Watch now
TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction Watch now

Part 2

Expert Interviews

10 sessions
MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Watch now
REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Watch now
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Watch now
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Watch now
DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF Watch now
NUDGE-FLU: Increasing Influenza Vaccination in HF Patients Watch now
DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF Watch now
TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure Watch now
Diagnosis in Heart Failure in Women Watch now
Dapagliflozin and Peripheral Arterial Disease in Heart Failure Watch now

About the episode

Dr Ross Campbell joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance. (NCT04860011)

In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice use of metolazone in addition to furosemide. 61 patients were enrolled into the study.

Findings suggest that both dapagliflozin and metolazone were well-tolerated and effective at treating diuretic resistance in this cohort of patients. 

Interview Questions:

  1. What is the rationale for this pragmatic trial?
  2. What was study design, patient population and outcome measures?
  3. What is the key data presented at HFA 23?
  4. What are the take-home messages of practicing clinicians?
  5. How do these findings complement the results of EMPEROR-Preserved and DELIVER?
  6. What are the next steps?

Faculty Biographies

Ross Campbell

View full profile

Comments

You must be to comment. If you are not registered, you can register here.